Search

Your search keyword '"Duangchinda, Thaneeya"' showing total 47 results
Start Over Author "Duangchinda, Thaneeya"
47 results on '"Duangchinda, Thaneeya"'

2. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination

Author

Assawakosri, Suvichada, Kanokudom, Sitthichai, Suntronwong, Nungruthai, Chansaenroj, Jira, Auphimai, Chompoonut, Nilyanimit, Pornjarim, Vichaiwattana, Preeyaporn, Thongmee, Thanunrat, Duangchinda, Thaneeya, Chantima, Warangkana, Pakchotanon, Pattarakul, Srimuan, Donchida, Thatsanathorn, Thaksaporn, Klinfueng, Sirapa, Sudhinaraset, Natthinee, Wanlapakorn, Nasamon, Mongkolsapaya, Juthathip, Honsawek, Sittisak, and Poovorawan, Yong

Published
2024
Full Text
View/download PDF

3. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination

Author

Assawakosri, Suvichada, Kanokudom, Sitthichai, Chansaenroj, Jira, Suntronwong, Nungruthai, Auphimai, Chompoonut, Nilyanimit, Pornjarim, Vichaiwattana, Preeyaporn, Thongmee, Thanunrat, Duangchinda, Thaneeya, Chantima, Warangkana, Pakchotanon, Pattarakul, Srimuan, Donchida, Thatsanatorn, Thaksaporn, Klinfueng, Sirapa, Sudhinaraset, Natthinee, Mongkolsapaya, Juthathip, Wanlapakorn, Nasamon, Honsawek, Sittisak, and Poovorawan, Yong

Published
2022
Full Text
View/download PDF

4. Immunogenicity and durability against micron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination

Author

Assawakosri, Suvichada, primary, Kanokudom, Sitthichai, additional, Suntronwong, Nungruthai, additional, Chansaenroj, Jira, additional, Auphimai, Chompoonut, additional, Nilyanimit, Pornjarim, additional, Vichaiwattana, Preeyaporn, additional, Thongmee, Thanunrat, additional, Duangchinda, Thaneeya, additional, Chantima, Warangkana, additional, Pakchotanon, Pattarakul, additional, Srimuan, Donchida, additional, Thatsanathorn, Thaksaporn, additional, Klinfueng, Sirapa, additional, Sudhinaraset, Natthinee, additional, Wanlapakorn, Nasamon, additional, Mongkolsapaya, Juthathip, additional, Honsawek, Sittisak, additional, and Poovorawan, Yong, additional

Published
2023
Full Text
View/download PDF

5. Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection.

Author

Suntronwong, Nungruthai, Kanokudom, Sitthichai, Auphimai, Chompoonut, Thongmee, Thanunrat, Assawakosri, Suvichada, Vichaiwattana, Preeyaporn, Yorsaeng, Ritthideach, Duangchinda, Thaneeya, Chantima, Warangkana, Pakchotanon, Pattarakul, Nilyanimit, Pornjarim, Srimuan, Donchida, Thatsanathorn, Thaksaporn, Sudhinaraset, Natthinee, Wanlapakorn, Nasamon, and Poovorawan, Yong

Subjects
SARS-CoV-2 Omicron variant, VACCINATION, SARS-CoV-2, IMMUNITY, COVID-19 vaccines
Abstract

Numerous studies have largely focused on short-term immunogenicity in recovered individuals post mRNA vaccination. However, understanding the long-term durability, particularly in inactivated and adenoviral vectored vaccines, remains limited. We evaluated antibody responses, omicron variant neutralization, and IFN-γ responses in 119 previously infected individuals vaccinated with CoronaVac or ChAdOx1 up to six months post-vaccination. Both vaccines elicited robust immune responses in recovered individuals, surpassing those who were infection-naïve, and these persisted above pre-vaccination levels for six months. However, antibody levels declined over time (geometric mean ratio (GMR) = 0.52 for both vaccines). Notably, neutralizing activities against omicron declined faster in ChAdOx1 (GMR = 0.6) compared to CoronaVac recipients (GMR = 1.03). While the first dose of ChAdOx1 adequately induced immune responses in recovered individuals, a second dose demonstrated advantages in omicron variant neutralization and slower decline. Although both vaccines induced T cell responses, the median IFN-γ level at six months returned to pre-vaccination levels. However, more individuals exhibited reactive T cell responses. Extending the interval (13–15 months) between infection and vaccination could enhance antibody levels and broaden neutralization. Together, these findings demonstrate a robust humoral and cellular response that was sustained for at least six months after vaccination, thus guiding optimal vaccination strategies based on prior infection and vaccine platforms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques

Author

Keelapang, Poonsook, primary, Ketloy, Chutitorn, additional, Puttikhunt, Chunya, additional, Sriburi, Rungtawan, additional, Prompetchara, Eakachai, additional, Sae-Lim, Malinee, additional, Siridechadilok, Bunpote, additional, Duangchinda, Thaneeya, additional, Noisakran, Sansanee, additional, Charoensri, Nicha, additional, Suriyaphol, Prapat, additional, Suparattanagool, Piyanan, additional, Utaipat, Utaiwan, additional, Masrinoul, Promsin, additional, Avirutnan, Panisadee, additional, Mongkolsapaya, Juthathip, additional, Screaton, Gavin, additional, Auewarakul, Prasert, additional, Malaivijitnond, Suchinda, additional, Yoksan, Sutee, additional, Malasit, Prida, additional, Ruxrungtham, Kiat, additional, Pulmanausahakul, Rojjanaporn, additional, and Sittisombut, Nopporn, additional

Published
2023
Full Text
View/download PDF

8. Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody

Author

Keelapang, Poonsook, primary, Kraivong, Romchat, additional, Pulmanausahakul, Rojjanaporn, additional, Sriburi, Rungtawan, additional, Prompetchara, Eakachai, additional, Kaewmaneephong, Jutamart, additional, Charoensri, Nicha, additional, Pakchotanon, Pattarakul, additional, Duangchinda, Thaneeya, additional, Suparattanagool, Piyanan, additional, Luangaram, Prasit, additional, Masrinoul, Promsin, additional, Mongkolsapaya, Juthathip, additional, Screaton, Gavin, additional, Ruxrungtham, Kiat, additional, Auewarakul, Prasert, additional, Yoksan, Sutee, additional, Malasit, Prida, additional, Puttikhunt, Chunya, additional, Ketloy, Chutitorn, additional, and Sittisombut, Nopporn, additional

Published
2023
Full Text
View/download PDF

9. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

Author

Dejnirattisai, Wanwisa, Wongwiwat, Wiyada, Supasa, Sunpetchuda, Zhang, Xiaokang, Dai, Xinghong, Rouvinski, Alexander, Jumnainsong, Amonrat, Edwards, Carolyn, Quyen, Nguyen Than Ha, Duangchinda, Thaneeya, Grimes, Jonathan M, Tsai, Wen-Yang, Lai, Chih-Yun, Wang, Wei-Kung, Malasit, Prida, Farrar, Jeremy, Simmons, Cameron P, Zhou, Z Hong, Rey, Felix A, Mongkolsapaya, Juthathip, and Screaton, Gavin R

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Vaccine Related, Prevention, Infectious Diseases, Immunization, Biotechnology, Rare Diseases, Vector-Borne Diseases, Biodefense, Emerging Infectious Diseases, Infection, Good Health and Well Being, Animals, Antibodies, Monoclonal, Antibodies, Neutralizing, Biological Assay, Cell Line, Dengue, Dengue Virus, Enzyme-Linked Immunosorbent Assay, Humans, Immunoblotting, Viral Envelope Proteins, Biochemistry and cell biology
Abstract

Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million infections occurring annually. To gain insight into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and fully neutralized virus produced in either insect cells or primary human cells, with 50% neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.

Published
2015

10. Neutralizing antibodies against omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity

Author

Suntronwong, Nungruthai, primary, Kanokudom, Sitthichai, additional, Assawakosri, Suvichada, additional, Vichaiwattana, Preeyaporn, additional, Klinfueng, Sirapa, additional, Phowatthanasathian, Harit, additional, Chansaenroj, Jira, additional, Srimuan, Donchida, additional, Thatsanathorn, Thaksaporn, additional, Duangchinda, Thaneeya, additional, Chantima, Warangkana, additional, Pakchotanon, Pattarakul, additional, Sudhinaraset, Natthinee, additional, Wanlapakorn, Nasamon, additional, and Poovorawan, Yong, additional

Published
2023
Full Text
View/download PDF

13. Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years

Author

Wanlapakorn, Nasamon, primary, Kanokudom, Sitthichai, additional, Phowatthanasathian, Harit, additional, Chansaenroj, Jira, additional, Suntronwong, Nungruthai, additional, Assawakosri, Suvichada, additional, Yorsaeng, Ritthideach, additional, Nilyanimit, Pornjarim, additional, Vichaiwattana, Preeyaporn, additional, Klinfueng, Sirapa, additional, Thongmee, Thanunrat, additional, Aeemjinda, Ratchadawan, additional, Khanarat, Nongkanok, additional, Srimuan, Donchida, additional, Thatsanatorn, Thaksaporn, additional, Chantima, Warangkana, additional, Pakchotanon, Pattarakul, additional, Duangchinda, Thaneeya, additional, Sudhinaraset, Natthinee, additional, and Poovorawan, Yong, additional

Published
2023
Full Text
View/download PDF

14. Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response

Author

Culshaw, Abigail, Ladell, Kristin, Gras, Stephanie, McLaren, James E, Miners, Kelly L, Farenc, Carine, van den Heuvel, Heleen, Gostick, Emma, Dejnirattisai, Wanwisa, Wangteeraprasert, Apirath, Duangchinda, Thaneeya, Chotiyarnwong, Pojchong, Limpitikul, Wannee, Vasanawathana, Sirijitt, Malasit, Prida, Dong, Tao, Rossjohn, Jamie, Mongkolsapaya, Juthathip, Price, David A, and Screaton, Gavin R

Published
2017
Full Text
View/download PDF

15. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination

Author

Assawakosri, Suvichada, primary, Kanokudom, Sitthichai, additional, Suntronwong, Nungruthai, additional, Chansaenroj, Jira, additional, Auphimai, Chompoonut, additional, Nilyanimit, Pornjarim, additional, Vichaiwattana, Preeyaporn, additional, Thongmee, Thanunrat, additional, Duangchinda, Thaneeya, additional, Chantima, Warangkana, additional, Pakchotanon, Pattarakul, additional, Srimuan, Donchida, additional, Thatsanatorn, Thaksaporn, additional, Klinfueng, Sirapa, additional, Sudhinaraset, Natthinee, additional, Wanlapakorn, Nasamon, additional, Mongkolsapaya, Juthathip, additional, Honsawek, Sittisak, additional, and Poovorawan, Yong, additional

Published
2022
Full Text
View/download PDF

16. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination

Author

Chatsiricharoenkul, Somruedee, primary, Niyomnaitham, Suvimol, additional, Posen, Harry Joshua, additional, Toh, Zheng Quan, additional, Licciardi, Paul V., additional, Wongprompitak, Patimaporn, additional, Duangchinda, Thaneeya, additional, Pakchotanon, Pattarakul, additional, Chantima, Warangkana, additional, and Chokephaibulkit, Kulkanya, additional

Published
2022
Full Text
View/download PDF

17. Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine

Author

Kanokudom, Sitthichai, primary, Assawakosri, Suvichada, additional, Suntronwong, Nungruthai, additional, Chansaenroj, Jira, additional, Auphimai, Chompoonut, additional, Nilyanimit, Pornjarim, additional, Vichaiwattana, Preeyaporn, additional, Thongmee, Thanunrat, additional, Yorsaeng, Ritthideach, additional, Duangchinda, Thaneeya, additional, Chantima, Warangkana, additional, Pakchotanon, Pattarakul, additional, Srimuan, Donchida, additional, Thatsanatorn, Thaksaporn, additional, Klinfueng, Sirapa, additional, Mongkolsapaya, Juthathip, additional, Sudhinaraset, Natthinee, additional, Wanlapakorn, Nasamon, additional, Honsawek, Sittisak, additional, and Poovorawan, Yong, additional

Published
2022
Full Text
View/download PDF

18. Effects of boosted mRNA and adenoviral‐vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination

Author

Suntronwong, Nungruthai, primary, Kanokudom, Sitthichai, additional, Auphimai, Chompoonut, additional, Assawakosri, Suvichada, additional, Thongmee, Thanunrat, additional, Vichaiwattana, Preeyaporn, additional, Duangchinda, Thaneeya, additional, Chantima, Warangkana, additional, Pakchotanon, Pattarakul, additional, Chansaenroj, Jira, additional, Puenpa, Jiratchaya, additional, Nilyanimit, Pornjarim, additional, Srimuan, Donchida, additional, Thatsanatorn, Thaksaporn, additional, Sudhinaraset, Natthinee, additional, Wanlapakorn, Nasamon, additional, Mongkolsapaya, Juthathip, additional, and Poovorawan, Yong, additional

Published
2022
Full Text
View/download PDF

20. Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination

Author

Suntronwong, Nungruthai, primary, Assawakosri, Suvichada, additional, Kanokudom, Sitthichai, additional, Yorsaeng, Ritthideach, additional, Auphimai, Chompoonut, additional, Thongmee, Thanunrat, additional, Vichaiwattana, Preeyaporn, additional, Duangchinda, Thaneeya, additional, Chantima, Warangkana, additional, Pakchotanon, Pattarakul, additional, Chansaenroj, Jira, additional, Nilyanimit, Pornjarim, additional, Srimuan, Donchida, additional, Thatsanatorn, Thaksaporn, additional, Sudhinaraset, Natthinee, additional, Wanlapakorn, Nasamon, additional, Mongkolsapaya, Juthathip, additional, and Poovorawan, Yong, additional

Published
2022
Full Text
View/download PDF

21. Development of a Singleplex Real-Time Reverse Transcriptase PCR Assay for Pan-Dengue Virus Detection and Quantification

Author

Songjaeng, Adisak, primary, Thiemmeca, Somchai, additional, Mairiang, Dumrong, additional, Punyadee, Nuntaya, additional, Kongmanas, Kessiri, additional, Hansuealueang, Prachya, additional, Tangthawornchaikul, Nattaya, additional, Duangchinda, Thaneeya, additional, Mongkolsapaya, Juthathip, additional, Sriruksa, Kanokwan, additional, Limpitikul, Wannee, additional, Malasit, Prida, additional, and Avirutnan, Panisadee, additional

Published
2022
Full Text
View/download PDF

22. Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination

Author

Assawakosri, Suvichada, primary, Kanokudom, Sitthichai, additional, Chansaenroj, Jira, additional, Suntronwong, Nungruthai, additional, Auphimai, Chompoonut, additional, Nilyanimit, Pornjarim, additional, Vichaiwattana, Preeyaporn, additional, Thongmee, Thanunrat, additional, Duangchinda, Thaneeya, additional, Chantima, Warangkana, additional, Pakchotanon, Pattarakul, additional, Srimuan, Donchida, additional, Thatsanatorn, Thaksaporn, additional, Klinfueng, Sirapa, additional, Sudhinaraset, Natthinee, additional, Wanlapakorn, Nasamon, additional, Mongkolsapaya, Juthathip, additional, Honsawek, Sittisak, additional, and Poovorawan, Yong, additional

Published
2022
Full Text
View/download PDF

23. Omicron BA.1, BA.2 and COVID-19 Booster Vaccination

Author

Assawakosri, Suvichada, primary, Kanokudom, Sitthichai, additional, Suntronwong, Nungruthai, additional, Puenpa, Jiratchaya, additional, Duangchinda, Thaneeya, additional, Chantima, Warangkana, additional, Pakchotanon, Pattarakul, additional, Mongkolsapaya, Juthathip, additional, Wanlapakorn, Nasamon, additional, Honsawek, Sittisak, additional, and Poovorawan, Yong, additional

Published
2022
Full Text
View/download PDF

24. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination

Author

Assawakosri, Suvichada, primary, Kanokudom, Sitthichai, additional, Suntronwong, Nungruthai, additional, Auphimai, Chompoonut, additional, Nilyanimit, Pornjarim, additional, Vichaiwattana, Preeyaporn, additional, Thongmee, Thanunrat, additional, Duangchinda, Thaneeya, additional, Chantima, Warangkana, additional, Pakchotanon, Pattarakul, additional, Srimuan, Donchida, additional, Thatsanatorn, Thaksaporn, additional, Klinfueng, Sirapa, additional, Yorsaeng, Ritthideach, additional, Sudhinaraset, Natthinee, additional, Wanlapakorn, Nasamon, additional, Mongkolsapaya, Juthathip, additional, Honsawek, Sittisak, additional, and Poovorawan, Yong, additional

Published
2022
Full Text
View/download PDF

25. COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron

Author

Suntronwong, Nungruthai, primary, Yorsaeng, Ritthideach, additional, Puenpa, Jiratchaya, additional, Auphimai, Chompoonut, additional, Thongmee, Thanunrat, additional, Vichaiwattana, Preeyaporn, additional, Kanokudom, Sitthichai, additional, Duangchinda, Thaneeya, additional, Chantima, Warangkana, additional, Pakchotanon, Pattarakul, additional, Assawakosri, Suvichada, additional, Nilyanimit, Pornjarim, additional, Klinfueng, Sirapa, additional, Wongsrisang, Lakkhana, additional, Srimuan, Donchida, additional, Thatsanatorn, Thaksaporn, additional, Sudhinaraset, Natthinee, additional, Wanlapakorn, Nasamon, additional, and Poovorawan, Yong, additional

Published
2022
Full Text
View/download PDF

27. Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans

Author

Dejnirattisai, Wanwisa, Jumnainsong, Amonrat, Onsirisakul, Naruthai, Fitton, Patricia, Vasanawathana, Sirijitt, Limpitikul, Wannee, Puttikhunt, Chunya, Edwards, Carolyn, Duangchinda, Thaneeya, Supasa, Sunpetchuda, Chawansuntati, Kriangkrai, Malasit, Prida, Mongkolsapaya, Juthathip, and Screaton, Gavin

Published
2010

28. Potent programmable antiviral against dengue virus in primary human cells by Cas13b RNP with short spacer and delivery by VLP

Author

Singsuksawat, Ekapot, primary, Onnome, Suppachoke, additional, Posiri, Pratsaneeyaporn, additional, Suphatrakul, Amporn, additional, Srisuk, Nittaya, additional, Nantachokchawapan, Rapirat, additional, Praneechit, Hansa, additional, Sae-kow, Chutimon, additional, Chidpratum, Pala, additional, Sa-ngiamsuntorn, Khanit, additional, Hongeng, Suradej, additional, Avirutnan, Panisadee, additional, Duangchinda, Thaneeya, additional, and Siridechadilok, Bunpote, additional

Published
2021
Full Text
View/download PDF

31. Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity1

Author

Midgley, Claire M., Flanagan, Aleksandra, Tran, Hai Bac, Dejnirattisai, Wanwisa, Chawansuntati, Kriangkrai, Jumnainsong, Amonrat, Wongwiwat, Wiyada, Duangchinda, Thaneeya, Mongkolsapaya, Juthathip, Grimes, Jonathan M., and Screaton, Gavin R.

Subjects
Mice, Inbred BALB C, Molecular Sequence Data, Virion, Antibodies, Monoclonal, Cross Reactions, Dengue Virus, Antibodies, Viral, Crystallography, X-Ray, Article, Protein Structure, Tertiary, Mice, Viral Envelope Proteins, Neutralization Tests, Animals, Female, Amino Acid Sequence, Binding Sites, Antibody, Serotyping
Abstract

Dengue virus infections are still increasing at an alarming rate in tropical and subtropical countries underlying the need for a dengue vaccine. Although it is relatively easy to generate antibody responses to dengue virus, low avidity or low concentrations of antibody may enhance infection of Fc receptor-bearing cells with clinical impact, posing a challenge to vaccine production. In this paper we report the characterization of a monoclonal antibody, 2H12, which is cross-reactive to all four serotypes in the dengue virus group. Crystal structures of 2H12-Fab in complex with domain III of the envelope protein from three dengue serotypes have been determined. 2H12 binds to the highly conserved AB loop of domain III of the envelope protein that is poorly accessible in the mature virion. 2H12 neutralization varied between dengue serotypes and strains; in particular, dengue serotype 2 was not neutralized. As the 2H12 binding epitope was conserved, this variation in neutralization highlights differences between dengue serotypes and suggests that significant conformational changes in the virus must take place for antibody binding. Surprisingly, 2H12 facilitated little or no enhancement of infection. These data provide a structural basis for understanding antibody neutralization and enhancement of infection, which is crucial for the development of future dengue vaccines.

Published
2012

32. Erratum: Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

Author

Dejnirattisai, Wanwisa, primary, Wongwiwat, Wiyada, additional, Supasa, Sunpetchuda, additional, Zhang, Xiaokang, additional, Dai, Xinghong, additional, Rouvinsky, Alexander, additional, Jumnainsong, Amonrat, additional, Edwards, Carolyn, additional, Quyen, Nguyen Than Ha, additional, Duangchinda, Thaneeya, additional, Grimes, Jonathan M, additional, Tsai, Wen-Yang, additional, Lai, Chih-Yun, additional, Wang, Wei-Kung, additional, Malasit, Prida, additional, Farrar, Jeremy, additional, Simmons, Cameron P, additional, Zhou, Z Hong, additional, Rey, Felix A, additional, Mongkolsapaya, Juthathip, additional, and Screaton, Gavin R, additional

Published
2015
Full Text
View/download PDF

33. Enhancing cross-reactive anti-prM dominates the human antibody response in dengue infection

Author

Dejnirattisai, Wanwisa, Jumnainsong, Amonrat, Onsirisakul, Naruthai, Fitton, Patricia, Vasanawathana, Sirijitt, Limpitikul, Wannee, Puttikhunt, Chunya, Edwards, Carolyn, Duangchinda, Thaneeya, Supasa, Sunpetchuda, Chawansuntati, Kriangkrai, Malasit, Prida, Mongkolsapaya, Juthathip, and Screaton, Gavin

Subjects
Encephalitis Virus, Japanese, viruses, Antibodies, Monoclonal, Dengue Vaccines, Receptors, Fc, U937 Cells, Cross Reactions, Dengue Virus, Antibodies, Viral, Virus Replication, Antibodies, Neutralizing, Antibody-Dependent Enhancement, Article, Monocytes, Cell Line, Dengue, Viral Matrix Proteins, Viral Envelope Proteins, Aedes, Animals, Humans, Serotyping, Antigens, Viral, Immune Evasion
Abstract

Dengue virus co-circulates as four serotypes, and sequential infections with more than one serotype are common. One hypothesis for the increased severity seen in secondary infections is antibody-dependent enhancement (ADE) leading to increased replication in Fc receptor-bearing cells. In this study, we have generated a panel of human monoclonal antibodies to dengue virus. Antibodies to the structural precursor-membrane protein (prM) form a major component of the response. These antibodies are highly cross-reactive among the dengue virus serotypes and, even at high concentrations, do not neutralize infection but potently promote ADE. We propose that the partial cleavage of prM from the viral surface reduces the density of antigen available for viral neutralization, leaving dengue viruses susceptible to ADE by antibody to prM, a finding that has implications for future vaccine design.

Published
2010

34. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

Author

Dejnirattisai, Wanwisa, primary, Wongwiwat, Wiyada, additional, Supasa, Sunpetchuda, additional, Zhang, Xiaokang, additional, Dai, Xinghong, additional, Rouvinski, Alexander, additional, Jumnainsong, Amonrat, additional, Edwards, Carolyn, additional, Quyen, Nguyen Than Ha, additional, Duangchinda, Thaneeya, additional, Grimes, Jonathan M, additional, Tsai, Wen-Yang, additional, Lai, Chih-Yun, additional, Wang, Wei-Kung, additional, Malasit, Prida, additional, Farrar, Jeremy, additional, Simmons, Cameron P, additional, Zhou, Z Hong, additional, Rey, Felix A, additional, Mongkolsapaya, Juthathip, additional, and Screaton, Gavin R, additional

Published
2014
Full Text
View/download PDF

35. Invariant NKT Cell Response to Dengue Virus Infection in Human

Author

Matangkasombut, Ponpan, primary, Chan-in, Wilawan, additional, Opasawaschai, Anunya, additional, Pongchaikul, Pisut, additional, Tangthawornchaikul, Nattaya, additional, Vasanawathana, Sirijitt, additional, Limpitikul, Wannee, additional, Malasit, Prida, additional, Duangchinda, Thaneeya, additional, Screaton, Gavin, additional, and Mongkolsapaya, Juthathip, additional

Published
2014
Full Text
View/download PDF

36. Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+T cell response

Author

Culshaw, Abigail, Ladell, Kristin, Gras, Stephanie, McLaren, James E, Miners, Kelly L, Farenc, Carine, van den Heuvel, Heleen, Gostick, Emma, Dejnirattisai, Wanwisa, Wangteeraprasert, Apirath, Duangchinda, Thaneeya, Chotiyarnwong, Pojchong, Limpitikul, Wannee, Vasanawathana, Sirijitt, Malasit, Prida, Dong, Tao, Rossjohn, Jamie, Mongkolsapaya, Juthathip, Price, David A, and Screaton, Gavin R

Abstract

Cross-reactivity to dengue virus serotypes can trigger life-threatening inflammation. Culshaw et al. show that germline-encoded components of dengue-virus-specific TCRs influence antigen engagament and suggest that ‘innate-like’ recognition of the virus might underpin harmful cross-reactivity.

Published
2017
Full Text
View/download PDF

37. Structural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-Reactivity

Author

Midgley, Claire M., primary, Flanagan, Aleksandra, additional, Tran, Hai Bac, additional, Dejnirattisai, Wanwisa, additional, Chawansuntati, Kriangkrai, additional, Jumnainsong, Amonrat, additional, Wongwiwat, Wiyada, additional, Duangchinda, Thaneeya, additional, Mongkolsapaya, Juthathip, additional, Grimes, Jonathan M., additional, and Screaton, Gavin R., additional

Published
2012
Full Text
View/download PDF

38. The development of a novel serotyping-NS1-ELISA to identify serotypes of dengue virus

Author

Puttikhunt, Chunya, primary, Prommool, Tanapan, additional, U-thainual, Nathaporn, additional, Ong-ajchaowlerd, Prapapun, additional, Yoosook, Kroong, additional, Tawilert, Chutithorn, additional, Duangchinda, Thaneeya, additional, Jairangsri, Aroonroong, additional, Tangthawornchaikul, Nattaya, additional, Malasit, Prida, additional, and Kasinrerk, Watchara, additional

Published
2011
Full Text
View/download PDF

40. T Cell Responses in Dengue Hemorrhagic Fever: Are Cross-Reactive T Cells Suboptimal?

Author

Mongkolsapaya, Juthathip, primary, Duangchinda, Thaneeya, additional, Dejnirattisai, Wanwisa, additional, Vasanawathana, Sirijit, additional, Avirutnan, Panisadee, additional, Jairungsri, Aroonroong, additional, Khemnu, Nuanpan, additional, Tangthawornchaikul, Nattaya, additional, Chotiyarnwong, Pojchong, additional, Sae-Jang, Kanokwan, additional, Koch, Michael, additional, Jones, Yvonne, additional, McMichael, Andrew, additional, Xu, Xiaoning, additional, Malasit, Prida, additional, and Screaton, Gavin, additional

Published
2006
Full Text
View/download PDF

43. Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.

Author

Dejnirattisai, Wanwisa, Wongwiwat, Wiyada, Supasa, Sunpetchuda, Zhang, Xiaokang, Dai, Xinghong, Rouvinsky, Alexander, Jumnainsong, Amonrat, Edwards, Carolyn, Quyen, Nguyen Than Ha, Duangchinda, Thaneeya, Grimes, Jonathan M, Tsai, Wen-Yang, Lai, Chih-Yun, Wang, Wei-Kung, Malasit, Prida, Farrar, Jeremy, Simmons, Cameron P, Zhou, Z Hong, Rey, Felix A, and Mongkolsapaya, Juthathip

Subjects
PUBLISHED errata, IMMUNOGLOBULINS, VIREMIA, DENGUE viruses, PERIODICAL publishing, PUBLISHING
Published
2015
Full Text
View/download PDF

44. An Engineered N-Glycosylated Dengue Envelope Protein Domain III Facilitates Epitope-Directed Selection of Potently Neutralizing and Minimally Enhancing Antibodies.

Author

Nilchan N, Kraivong R, Luangaram P, Phungsom A, Tantiwatcharakunthon M, Traewachiwiphak S, Prommool T, Punyadee N, Avirutnan P, Duangchinda T, Malasit P, and Puttikhunt C

Abstract

The envelope protein of dengue virus (DENV) is a primary target of the humoral immune response. The domain III of the DENV envelope protein (EDIII) is known to be the target of multiple potently neutralizing antibodies. One such antibody is 3H5, a mouse antibody that binds strongly to EDIII and potently neutralizes DENV serotype 2 (DENV-2) with unusually minimal antibody-dependent enhancement (ADE). To selectively display the binding epitope of 3H5, we strategically modified DENV-2 EDIII by shielding other known epitopes with engineered N-glycosylation sites. The modifications resulted in a glycosylated EDIII antigen termed "EDIII mutant N". This antigen was successfully used to sift through a dengue-immune scFv-phage library to select for scFv antibodies that bind to or closely surround the 3H5 epitope. The selected scFv antibodies were expressed as full-length human antibodies and showed potent neutralization activity to DENV-2 with low or negligible ADE resembling 3H5. These findings not only demonstrate the capability of the N-glycosylated EDIII mutant N as a tool to drive an epitope-directed antibody selection campaign but also highlight its potential as a dengue immunogen. This glycosylated antigen shows promise in focusing the antibody response toward a potently neutralizing epitope while reducing the risk of antibody-dependent enhancement.

Published
2024
Full Text
View/download PDF

45. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3-4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination.

Author

Assawakosri S, Kanokudom S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanathorn T, Klinfueng S, Sudhinaraset N, Wanlapakorn N, Mongkolsapaya J, Honsawek S, and Poovorawan Y

Abstract

Background: Several countries have authorized a booster vaccine campaign to combat the spread of COVID-19. Data on persistence of booster vaccine-induced immunity against new Omicron subvariants are still limited. Therefore, our study aimed to determine the serological immune response of COVID-19 booster after CoronaVac-priming., Methods: A total of 187 CoronaVac-primed participants were enrolled and received an inactivated (BBIBP), viral vector (AZD1222) or mRNA vaccine (full-/half-dose BNT162B2, full-/half-dose mRNA-1273) as a booster dose. The persistence of humoral immunity both binding and neutralizing antibodies against wild-type and Omicron was determined on day 90-120 after booster., Results: A waning of total RBD immunoglobulin (Ig) levels, anti -RBD IgG, and neutralizing antibodies against Omicron BA.1, BA.2, and BA.4/5 variants was observed 90-120 days after booster vaccination. Participants who received mRNA-1273 had the highest persistence of the immunogenicity response, followed by BNT162b2, AZD1222, and BBIBP-CorV. The responses between full and half doses of mRNA-1273 were comparable. The percentage reduction of binding antibody ranged from 50 % to 75 % among all booster vaccine., Conclusions: The antibody response substantially waned after 90-120 days post-booster dose. The heterologous mRNA and the viral vector booster demonstrated higher detectable rate of humoral immune responses against the Omicron variant compared to the inactivated BBIBP booster. Nevertheless, an additional fourth dose is recommended to maintain immune response against infection., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 The Authors.)

Published
2023
Full Text
View/download PDF

46. Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.

Author

Wanlapakorn N, Kanokudom S, Phowatthanasathian H, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P, Vichaiwattana P, Klinfueng S, Thongmee T, Aeemjinda R, Khanarat N, Srimuan D, Thatsanatorn T, Chantima W, Pakchotanon P, Duangchinda T, Sudhinaraset N, and Poovorawan Y

Subjects
Child, Child, Preschool, Humans, Antibodies, Neutralizing, Antibodies, Viral, BNT162 Vaccine, Immunogenicity, Vaccine, Prospective Studies, RNA, Messenger, SARS-CoV-2, mRNA Vaccines, COVID-19 prevention & control, COVID-19 Vaccines adverse effects
Abstract

To compare the reactogenicity and immunogenicity between the two-dose mRNA COVID-19 vaccine regimen and one or two doses of inactivated vaccine followed by an mRNA vaccine regimen in healthy children between 5 and 11 years of age, a prospective cohort study was performed at King Chulalongkorn Memorial Hospital in Thailand between March to June 2022. Healthy children between 5 and 11 years of age were enrolled and received the two-dose mRNA COVID-19 vaccine (BNT162b2) regimen or the inactivated (CoronaVac) vaccine followed by the BNT162b2 vaccine regimen. In addition, healthy children who received two doses of BBIBP-CorV between 1 and 3 months prior were enrolled to receive a heterologous BNT162b2 as a third dose (booster). Reactogenicity was assessed by a self-reported online questionnaire. Immunogenicity analysis was performed to determine binding antibodies to wild-type SARS-CoV-2. Neutralizing antibodies to Omicron variants (BA.2 and BA.5) were tested using the focus reduction neutralization test. Overall, 166 eligible children were enrolled. Local and systemic adverse events which occurred within 7 days after vaccination were mild to moderate and well-tolerated. The two-dose BNT162b2, CoronaVac followed by BNT162b2, and two-dose BBIBP-CorV followed by BNT162b2 groups elicited similar levels of anti-receptor-binding domain (RBD) IgG. However, the two-dose BNT162b2 and two-dose BBIBP-CorV followed by BNT162b2 groups elicited higher neutralizing activities against the Omicron BA.2 and BA.5 variant than the CoronaVac followed by BNT162b2 group. The CoronaVac followed by BNT162b2 group elicited low neutralizing activities against the Omicron BA.2 and BA.5 variant. A third dose (booster) mRNA vaccine should be prioritized for this group., (© 2023 Wiley Periodicals LLC.)

Published
2023
Full Text
View/download PDF

47. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac ® , ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination.

Author

Chatsiricharoenkul S, Niyomnaitham S, Posen HJ, Toh ZQ, Licciardi PV, Wongprompitak P, Duangchinda T, Pakchotanon P, Chantima W, and Chokephaibulkit K

Subjects
Humans, SARS-CoV-2, ChAdOx1 nCoV-19, BNT162 Vaccine, Pilot Projects, Antibodies, Neutralizing, Vaccination adverse effects, Immunoglobulin G, COVID-19 Vaccines adverse effects, COVID-19 prevention & control
Abstract

There is a limited supply of COVID-19 vaccines, with less than 20% of eligible populations in low-income countries having received one dose. Intradermal delivery of fractional dose vaccines is one way to improve global vaccine access, but no studies have reported data on intradermal delivery of COVID-19 primary series vaccination. We conducted a pilot study to examine the safety and immunogenicity of three intradermal primary series regimens - heterologous regimen of CoronaVac and ChAdOx1 (CoronaVac-ChAdOx1), homologous regimen of ChAdOx1 (ChAdOx1-ChAdOx1), and homologous regimen of BNT162b2 (BNT162b2-BNT162b2). Each dose was 1/5 th or 1/6 th of the standard dose. Two additional exploratory arms of intradermal vaccination for the second dose following an intramuscular first dose of ChAdOx1 and BNT162b2 were included. Intradermal vaccination was found to be immunogenic and safe. The antibody responses generated by the intradermal primary series were highest in the BNT162b2 arms. The anti-receptor binding domain (anti-RBD) IgG concentration following fractional dose intradermal vaccination was similar to that of standard dose intramuscular vaccination of the same regimen for all study arms except for BNT162b2. The BNT162b2 intradermal series generated a lower antibody concentration than the reference intramuscular series, despite generating the highest antibody concentration of all three intradermal primary series regimens. Neutralizing antibody responses against the SARS-CoV-2 ancestral strain were consistent with what was observed for anti-RBD IgG, with lower titers for SARS-CoV-2 variants. Neutralizing titers were lowest against the omicron variant, being undetectable in about a quarter of study participants. T-cell responses against spike- and nucleocapsid-membrane-open reading frame proteins were also detected following intradermal vaccination. Adverse effects following intradermal vaccination were generally comparable with post-intramuscular vaccination effects. Taken together, our data suggest that intradermal vaccination using 1/5 th or 1/6 th of standard COVID-19 intramuscular vaccination dosing were immunogenic with tendency of lower systemic adverse reactions than intramuscular vaccination. Our findings have implications in settings where COVID-19 vaccines are in shortage., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Chatsiricharoenkul, Niyomnaitham, Posen, Toh, Licciardi, Wongprompitak, Duangchinda, Pakchotanon, Chantima and Chokephaibulkit.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results